Name | ac-yvad-cmk |
---|---|
Synonyms |
Ac-YVAD-cmk
N-Ac-Tyr-Val-Ala-Asp-CMK AC-TYR-VAL-ALA-ASP-CHLOROMETHYLKETONE AC-YVAD-CHLOROMETHYLKETONE AC-TYR-VAL-ALA-ASP-CH2CL AC-TYR-VAL-ALA-ASP-CMK N-Acetyl-L-tyrosyl-L-valyl-N-[(2S)-1-carboxy-4-chloro-3-oxobutan-2-yl]-L-alaninamide PASE-1 INHIBITOR II ICE INHIBITOR II IL-1BETA CONVERTING ENZYME INHIBITOR II L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-1-(carboxymethyl)-3-chloro-2-oxopropyl]- AC-TYR-ALA-ASP-CHLOROMETHYLKETONE N-Acetyl-L-tyrosyl-L-valyl-N-[(2S)-1-carboxy-4-chloro-3-oxo-2-butanyl]-L-alaninamide |
Description | Ac-YVAD-cmk (Caspase-1 Inhibitor II) is a selective caspase-1 (IL-1beta converting enzyme, ICE)) inhibitor with neuroprotective and anti-inflammatory effects. Ac-YVAD-cmk effectively suppresses the expression of IL-1β and IL-18. Ac-YVAD-cmk inhibits pyroptosis in many diseases[1][2]. |
---|---|
Related Catalog | |
Target |
Caspase-1 |
In Vitro | Ac-YVAD-cmk (40 μM or 80 μM) reduces the expression of IL-1β and IL-18 in activated microglia in vitro[2]. |
In Vivo | Ac-YVAD-cmk treatment (1 μg/rats; SD rat; injected into the left lateral ventricle) significantly decreases the protein levels of caspase-1 (p20), mature IL-1β/IL-18 compared with the ICH group[2]. Ac-YVAD-cmk (rats with ac-YVAD-cmk at a dose of 12.5 μmol/kg) significantly reduces mortality from 83 to 33% using Log Rank analysis[3]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 969.1±65.0 °C at 760 mmHg |
Molecular Formula | C24H33ClN4O8 |
Molecular Weight | 540.994 |
Flash Point | 539.9±34.3 °C |
Exact Mass | 540.198669 |
PSA | 191.00000 |
LogP | 1.93 |
Vapour Pressure | 0.0±0.3 mmHg at 25°C |
Index of Refraction | 1.554 |
Storage condition | -20°C |
RIDADR | NONH for all modes of transport |
---|---|
WGK Germany | 3 |
RTECS | AY3079566 |